Sign In
Buy ADPT
$15.99
+0.85 (+5.61%)
At Close: Jun 03, 2026
Adaptive Biotechnologies Highlights clonoSEQ Growth, 2026 Cash Flow Goal at Conference
06:05pm, Wednesday, 03'rd Jun 2026
Adaptive Biotechnologies NASDAQ: ADPT Chief Executive Officer and Co-Founder Chad Robins said the company is focused on expanding its minimal residual disease testing business while pursuing targeted
Over 30 presentations at ASCO and EHA leverage clonoSEQ MRD testing to assess novel therapies and support MRD-guided patient care across blood cancers
Harvest Investment Services Dumps 356,000 Adaptive Biotechnologies (ADPT) Shares Worth $5.7 Million
04:03pm, Tuesday, 26'th May 2026
Adaptive Biotechnologies develops immune-driven diagnostics and research tools for the life sciences and healthcare sectors.
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
04:17pm, Thursday, 21'st May 2026
SEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune syste
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
04:17pm, Thursday, 21'st May 2026
SEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune syste
Adaptive Biotechnologies Corporation (ADPT) Q1 2026 Earnings Call Transcript
10:21pm, Tuesday, 05'th May 2026
Adaptive Biotechnologies Corporation (ADPT) Q1 2026 Earnings Call Transcript
Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
07:31pm, Tuesday, 05'th May 2026
While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Beats Revenue Estimates
07:05pm, Tuesday, 05'th May 2026
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.2 per share a year ago.
Adaptive Biotechnologies Reports First Quarter 2026 Financial Results
04:05pm, Tuesday, 05'th May 2026
SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the gene
Adaptive Biotechnologies' Chief Operating Officer Sold Over 19,000 Company Shares. Here's What That Means for Investors.
05:29pm, Monday, 04'th May 2026
This immune diagnostics innovator reported a notable insider sale as it advances platforms for disease detection and monitoring.
Adaptive Biotechnologies' COO Is Running a Systematic Sell Program — Here's What It Means
08:52am, Monday, 20'th Apr 2026
This immune diagnostics firm reported a notable insider sale as it expands its clinical portfolio and strategic partnerships.
Should You Sell Adaptive Biotechnologies (ADPT) After Its President and COO Sold 57,000 Shares?
10:37am, Saturday, 18'th Apr 2026
57,180 shares were sold for a total transaction value of approximately ~$826,000 across multiple days ending April 16, 2026. This sale represented 12.29% of Rubinstein's direct holdings at the time, r
Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026
04:05pm, Wednesday, 15'th Apr 2026
SEATTLE, April 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune sys
Julie Rubinstein Sells 19,060 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock
04:58am, Wednesday, 15'th Apr 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) COO Julie Rubinstein sold 19,060 shares of the company's stock in a transaction that occurred on Monday, April 13th. The shares we
Adaptive Biotech Insider Sells $554K as Revenue Jumps 55%, but Here's What Investors Should Focus On
09:13am, Wednesday, 08'th Apr 2026
The President and COO of Adaptive Biotechnologies Corporation reported the sale of 38,120 shares for about $554,000, based on a weighted average transaction price of $14.53 per share across April 1–
